Big Board

Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Avastin and Tecentriq combination wins approval in China and Europe
2 Bio-Thera Solutions Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)
3 European Commission approves Roche's Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
4 NICE recommends Tecentriq and Avastin in advanced or unresectable HCC
5 Roche gets EC approval for Tecentriq-Avastin combo to treat liver cancer
6 Bio-Thera Solutions Files for EU Bevacizumab Approval
7 Tecentriq-Avastin Combo Approved in Europe for Advanced or...
8 Genentech Files to Block Marketing of Centus' Bevacizumab Biosimilar
9 First report card on biosimilars in oncology
10 The European Commission has approved Roche's Tecentriq in conjunction with Avastin
11 Henlius, Celltrion Group Report Product Development Advances
12 EU Approves Olaparib in Combination with Bevacizumab to Treat Advanced Ovarian Cancer
13 Beovu offers model on how to handle unexpected complications
14 Avastin Market 2018- Manufacturers, Future Growth, Regional Development and Forecasts Report
15 Very low-dose Avastin effective for preventing blindness in preterm infants
16 European advisory group backs Samsung Bioepis' Avastin biosimilar
17 Bio-Thera Ventures Outside China With European Bevacizumab Filing
18 When Is Bevacizumab (Avastin) Recommended and What Are the Side Effects?
19 Systemic Therapy Advances Provide More Treatment Options in HCC
20 Avastin is used more for Colorectal Cancer compared to Ovarian, Brain, Lung, and Fallopian Tube Cancer
21 Tecentriq Plus Avastin Now Approved for Liver Cancer
22 Prestige Biopharma Licenses Trastuzumab Biosimilar to Teva Israel
23 Avastin Market Size, Trends, Growth, Scope, Overall Analysis and Forecast by 2027
25 Offering Avastin for wet AMD is legal, says appeal court
26 Tecentriq brings no benefit to Avastin and chemo combo in ovarian cancer
27 Early-Stage Study Details Similarity of Bevacizumab Biosimilar to Avastin
28 FDA Approves Combination of Lynparza and Avastin as Maintenance Treatment for Advanced Ovarian Cancer
29 Genentech's Tecentriq-Avastin Combo Approved for HCC, an Improvement on Standard of Care
30 Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
31 FDA Approves Genentech's Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer
32 What You Need to Know About the FDA's Approval of Lynparza and Avastin for Advanced Ovarian Cancer
33 Bio-Thera Solutions and BeiGene Announce License, Distribution, and Supply Agreement for Avastin® (Bevacizumab) Biosimilar BAT1706 in China
34 Tecentriq Plus Avastin Approved as First-Line Treatment for Advanced HCC
35 FDA approves Roche's Tecentriq in combination with Avastin for people with the most common form of liver cancer
36 NMPA Accepts Bio-Thera Solutions' Biologics License Application (BLA) for BAT1706, A Proposed Biosimilar to Avastin®
37 Roche Tecentriq, Avastin combo gets positive CHMP opinion for liver cancer
38 FDA Approves Tecentriq-Avastin Combo for Newly Diagnosed Advanced...
39 African Platform Eyes $750m Investment :: Generics Bulletin
40 FDA Approves Lynparza® Plus Avastin® Combo for Gynecologic Cancers
41 Zejula-Avastin Combo Showing Efficacy in Advanced Ovarian Cancer in Trial
42 Combination of Avastin and Tarceva 'Should Be Considered Preferred Option' in Kidney Cancer Subtype
43 Week In Review: Eluminex Raises $50 Million For Ophthalmology Drugs
44 BRIEF—Chugai gets nod for new use of Tecentriq and Avastin
45 Novartis, Roche/Genentech face major fines from French regulatory authority
46 FDA starts speedy review of Lynparza plus Avastin in ovarian cancer
47 Options For Ovarian Cancer Maintenance Therapy: PARP Inhibitors & Avastin
48 Centus' Avastin Biosimilar Receives EC Approval
49 UNC Researchers Identify Genetic Variant Linked to Drug-Induced Hypertension with Avastin®
50 ReSPECT Study Shows Positive Results in Recurrent Glioblastoma
51 Novartis, Roche fined $528M for anti-competition scheme in France
52 Tecentriq-Avastin Combo for Liver Cancer Recommended for EU Approval
53 UK court imposes safety rules on off-label use of Avastin in wet-AMD
54 Chugai wins additional HCC indication for Tecentriq and Avastin combo
55 FDA Accepts BLA for Bevacizumab Biosimilar
56 Roche files Tecentriq/Avastin combo in liver cancer
57 Age Related Macular Degeneration Treatment Market – Covid-19 Impact Research Reports, Size, Share, Industry Trends, Growth Insight, Share, Competitive Analysis, Statistics, Regional, And Industry Forecast
58 Centus bags approval for Avastin biosimilar in Europe
59 Roche’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
60 Biosimilar Avastin Is Launched In India :: Generics Bulletin
61 China Sees Flurry Of Activity On Avastin
62 Mylan's Bevacizumab Biosimilar Gains Decision Date
63 Bio-Thera Solutions Announces Positive Top-Line Results for BAT1706, A Proposed Biosimilar to Avastin®
64 ImmunoGen Announces Initial Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status
65 Proposed Avastin Biosimilar Gets CHMP Nod
66 Bevacizumab step therapy for wet AMD may be effective for majority of patients
67 AryoGen Bevacizumab Biosimilar Compares To Avastin :: Generics Bulletin
68 Roche's $7 Billion Drug Sales At Risk?
69 Roche's Tecentriq/Avastin combo wins US approval
70 Litigation on Amgen's Biosimilar to Avastin Settles on Heels of Amgen Procedural Victory at Federal Circuit
71 FDA Approves Lynparza/Avastin With Myriad Genetics CDx for Platinum-Sensitive Ovarian Cancer
72 EMA Committee Recommends Approval of Lynparza, Avastin in Platinum-Sensitive Ovarian Cancer
73 AryoGen’s bevacizumab biosimilar BE1040V found noninferior to AVASTIN in phase III study
74 FDA approves Zirabev, biosimilar to Avastin
75 Innovent and Coherus Strike Licensing Agreement for Avastin Biosimilar
76 ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO
77 Genentech's Tecentriq-Avastin Combo Improves Survival in Liver Cancer
78 Novartis and Roche Fined $526 Million for Lucentis Marketing Foibles
79 Atezolizumab/Bevacizumab Lays the Groundwork for Optimal Sequencing in HCC
80 Coherus Acquires Commercial Rights for Avastin® Biosimilar in the United States
81 In Patients With NSCLC Relapsing Shortly After Frontline Therapy Initiation, Ramucirumab Combination Impresses
82 Bio-Thera Solutions sells China Avastin biosimilar rights for up to $165M
83 BREAKING NEWS: Genentech and Amgen Settle HERCEPTIN and AVASTIN Biosimilar Disputes
84 Ovarian Cancer Therapeutics Market: Rising incidence of ovarian cancer to drive the market
85 Amgen, Pfizer biosimilar sales pressure top drugs
86 A Targeted Ovarian Cancer Treatment– The Role of Avastin (Bevacizumab)
87 Pfizer Launches Bevacizumab Biosimilar, Zirabev, in the United States
88 Why is Tecentriq+Avastin potent primary therapy for liver cancer?
89 Roche files Tecentriq, Avastin combo as a liver cancer therapy
90 Avastin (bevacizumab) Drug / Medicine Information
91 Avastin Improves Quality of Life for Mesothelioma Patients
92 FDA Reviewing Lynparza-Avastin for Certain Ovarian Cancer Indications
93 Mirvetuximab Soravtansine-Avastin Combo Promising for Recurrent OC
94 What Does a New Ovarian Cancer Drug Combo Approval Mean for Patients?
95 Samsung Bioepis Receives European Commission Approval for AYBINTIO® (Bevacizumab)
96 Updated: Multiple Biosimilars To Avastin Have Launched In EU
97 ESMO: Roche, after Tecentriq's ovarian cancer fail, banks hopes on final survival analysis
98 Proposed Bevacizumab Biosimilar for mCRC Found Noninferior to Reference Drug
99 Bevacizumab Biosimilar Under Review by FDA
100 Renal Cell Cacinoma Drugs Market Size 2020 Demand, Global Trend, News, Business Growth, Top Key Players Update, Business Statistics and Research Methodology by Forecast to 2026